NovAliX SAS, of Strasbourg, France, signed a drug discovery collaboration with Galapagos NV, of Mechelen, Belgium, in the field of osteoarthritis. Under the terms, NovAliX will handle the discovery of specific small-molecule lead candidates for a target chosen by Galapagos and then will identify hits using its Graffinity fragment-based screening technology. In exchange, NovAliX will receive technology access fees, research funding and potential milestones. Specific financial terms were not disclosed.